Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 29603722.
- Also identified by DOI 10.1111/bjd.16607.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We present the case of a 77-year-old male patient with more than 50 basal cell carcinomas on the head and upper trunk. The patient did not respond to several lines of treatment, including surgery, imiquimod, retinoids, itraconazole and therapy with the hedgehog inhibitor vismodegib. The patient responded well to off-label therapy with the anti-programmed death-1 antibody pembrolizumab after four infusions.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Basal Cell Nevus Syndrome
- Programmed Cell Death 1 Receptor
- Repressor Proteins
- Skin Neoplasms